Blackstone and TPG in advanced talks for $17B Hologic

Blackstone and TPG are reported to be in advanced negotiations to acquire Hologic, in a transaction that sources say could top $17bn including debt. If finalised, the proposed take-private would rank among the largest private equity buyouts globally this year and underscores continued investor appetite for healthcare platforms with strong secular growth.

According to market contacts, the consortium is discussing a purchase price that would imply a cash offer of generally above $75 per share — a meaningful premium to Hologic's most recent close at $69.85. The figure reported includes assumed debt and financing costs; negotiations remain fluid and no binding agreement has been announced.

Hologic, a Massachusetts-based medtech company focused on diagnostics and devices for women’s health, occupies a strategically attractive niche: ageing populations, rising diagnostic adoption and ongoing demand for specialised women’s health solutions. That market positioning helps explain why buyout firms are willing to contemplate sizeable leverage and a multi-billion dollar enterprise valuation.

Private equity sponsors are typically expected to structure deals of this magnitude with a mix of equity and syndicated debt; with credit markets calmer than in previous years and dry powder still elevated across the industry, sponsors have the financial firepower to pursue larger transactions. Industry estimates put global private equity dry powder well into the trillions, supporting a wave of large-cap healthcare deals despite rising interest rates earlier in the cycle.

For Hologic, a private-equity sale would mean new ownership focused on operational optimisation, potential bolt-on consolidation and capital allocation away from the public-market reporting cycle. For regulators and lenders, the scale of the financing and the strategic importance of medical-device businesses can raise scrutiny around competition, supply resilience and post-deal leverage levels.

Market participants caution that advanced talks do not guarantee a deal: parties can still walk away or alter terms before a definitive agreement is signed. Should the transaction proceed, it will offer a fresh signal about the sector’s appeal to deep-pocketed sponsors and may prompt further activity as PE firms chase differentiated healthcare assets with predictable revenue streams.